GILD Gilead Sciences, Inc.
$150.93
Gilead Sciences, Inc. (GILD) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is $2.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.0% since its last earnings release on August 4, 2026.
Gilead Sciences Beat Consensus Estimates, Raises Guidance
Tuesday, August 4, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 4:00 PM ET
Earnings Whisper
-
vs $2.15
Rev est $7.79B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$144.16
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Gilead Sciences, Inc.
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.
Sector
Healthcare
Industry
Biotechnology
Held By 15 ETFs, by dollar flow
- QQQ Invesco QQQ Trust
- QQQ Invesco QQQ Trust
- OEF iShares S&P 100 ETF
- OEF iShares S&P 100 ETF
- QTOP iShares Nasdaq Top 30 Stocks ETF
- QTOP iShares Nasdaq Top 30 Stocks ETF
- MOAT VanEck Morningstar Wide Moat ETF
- MOAT VanEck Morningstar Wide Moat ETF
- DVY iShares Select Dividend ETF
- DVY iShares Select Dividend ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- HDV iShares Core High Dividend ETF
Charts powered in part by Lightweight Charts™ by TradingView.